Application of Extracorporeal Apheresis in Treatment of COVID-19: a Rapid Review

Bionanoscience. 2022;12(3):979-993. doi: 10.1007/s12668-022-00987-x. Epub 2022 May 12.

Abstract

Spread of a novel coronavirus infection in 2019 caused by SARS-CoV-2 virus has become a real threat to public health all around the world. The new pandemic required the mobilization of all resources for effective treatment of COVID-19 patients. Extracorporeal apheresis methods were suggested as an addition to the therapy of severe COVID-19 patients, especially when there is a threat of cytokine storm. Cytokine storm has a complex and not fully understood mechanism, and it can result in the multiple organ failure syndrome, associated with high mortality. The main cytokines that play the key role in the cytokine storm are IL-6, IL-10, and TNF-alpha. Removal of the target pro-inflammatory cytokines from the bloodstream can be beneficial in reducing the risk of complications as well as the mortality rate. We describe and compare different methods of extracorporeal apheresis: hemoadsorption, selective plasma filtration, and plasma exchange therapy in the context of their potential use in COVID-19 treatment.

Keywords: COVID-19; Extracorporeal apheresis; Hemoadsorbtion; Selective plasma filtration; Therapeutic plasma exchange.

Publication types

  • Review